These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 16175829)

  • 21. The economics of effective AIDS treatment in Thailand.
    Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bridging the gap between antiretroviral access and adherence in Mexico.
    Campero L; Herrera C; Kendall T; Caballero M
    Qual Health Res; 2007 May; 17(5):599-611. PubMed ID: 17478643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inequalities and healthcare reform in Chile: equity of what?
    Burrows J
    J Med Ethics; 2008 Sep; 34(9):e13. PubMed ID: 18757613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Provision of HIV treatment in HIV preventive vaccine trials: a developing country perspective.
    Slack C; Stobie M; Milford C; Lindegger G; Wassenaar D; Strode A; Ijsselmuiden C
    Soc Sci Med; 2005 Mar; 60(6):1197-208. PubMed ID: 15626517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global AIDS: new challenges for health and human rights.
    Farmer P
    Perspect Biol Med; 2005; 48(1):10-6. PubMed ID: 15681875
    [No Abstract]   [Full Text] [Related]  

  • 26. Adherence as therapeutic citizenship: impact of the history of access to antiretroviral drugs on adherence to treatment.
    Nguyen VK; Ako CY; Niamba P; Sylla A; Tiendrébéogo I
    AIDS; 2007 Oct; 21 Suppl 5():S31-5. PubMed ID: 18090265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The (political) economics of antiretroviral treatment in developing countries.
    Nattrass NJ
    Trends Microbiol; 2008 Dec; 16(12):574-9. PubMed ID: 18964022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.
    Jordan MR; Bennett DE; Bertagnolio S; Gilks CF; Sutherland D
    Antivir Ther; 2008; 13 Suppl 2():15-23. PubMed ID: 18575188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Explicit rationing of elective services: implementing the New Zealand reforms.
    Dew K; Cumming J; McLeod D; Morgan S; McKinlay E; Dowell A; Love T
    Health Policy; 2005 Sep; 74(1):1-12. PubMed ID: 16098407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is it ethical to study what ought not to happen?
    Rennie S
    Dev World Bioeth; 2006 May; 6(2):71-7. PubMed ID: 16594969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining prevention, treatment and care: lessons from South Africa.
    Achmat Z; Simcock J
    AIDS; 2007 Jul; 21 Suppl 4():S11-20. PubMed ID: 17620746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationing access to public-sector antiretroviral treatment during scale-up in South Africa: implications for equity.
    Jacobs N; Schneider H; Van Rensburg HC
    Afr J AIDS Res; 2008 May; 7(1):19-27. PubMed ID: 25871268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Free care at the point of service delivery: a key component for reaching universal access to HIV/AIDS treatment in developing countries.
    Souteyrand YP; Collard V; Moatti JP; Grubb I; Guerma T
    AIDS; 2008 Jul; 22 Suppl 1():S161-8. PubMed ID: 18664948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Equity of access to elective surgery: reflections from NZ clinicians.
    McLeod D; Dew K; Morgan S; Dowell A; Cumming J; Cormack D; McKinlay E; Love T
    J Health Serv Res Policy; 2004 Oct; 9 Suppl 2():41-7. PubMed ID: 15511325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The obligation to provide antiretroviral treatment in HIV prevention trials.
    Lo B; Padian N; Barnes M
    AIDS; 2007 Jun; 21(10):1229-31. PubMed ID: 17545698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [AIDS treatment in Africa: the risk of antiretroviral resistance].
    Hamers RL; Schuurman R; van Vugt M; Derdelinckx I; Rinke de Wit TF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(48):2666-71. PubMed ID: 18179083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hard choices: rationing antiretroviral therapy for HIV/AIDS in Africa.
    Rosen S; Sanne I; Collier A; Simon JL
    Lancet; 2005 Jan 22-28; 365(9456):354-6. PubMed ID: 15664233
    [No Abstract]   [Full Text] [Related]  

  • 38. Ethical issues in the NIMH Collaborative HIV/STD Prevention Trial.
    NIMH Collaborative HIV/STD Prevention Trial Group
    AIDS; 2007 Apr; 21 Suppl 2():S69-80. PubMed ID: 17413266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The challenges to scaling up antiretroviral therapy in Papua New Guinea.
    Raynes P; Maibani G
    P N G Med J; 2006; 49(1-2):32-42. PubMed ID: 18396610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Provision of antiretroviral therapy in South Africa: unique challenges and remaining obstacles.
    Ojikutu B; Jack C; Ramjee G
    J Infect Dis; 2007 Dec; 196 Suppl 3():S523-7. PubMed ID: 18181705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.